SG Americas Securities LLC Raises Position in Charles River Laboratories International, Inc. $CRL

SG Americas Securities LLC grew its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 2.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 186,173 shares of the medical research company’s stock after acquiring an additional 4,395 shares during the period. SG Americas Securities LLC owned about 0.38% of Charles River Laboratories International worth $32,115,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of CRL. Tema Etfs LLC purchased a new position in Charles River Laboratories International during the fourth quarter valued at $26,000. Los Angeles Capital Management LLC purchased a new stake in Charles River Laboratories International in the fourth quarter worth about $42,000. Sfam LLC purchased a new stake in Charles River Laboratories International in the fourth quarter worth about $43,000. Activest Wealth Management raised its stake in shares of Charles River Laboratories International by 10,900.0% in the fourth quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock worth $44,000 after buying an additional 218 shares during the period. Finally, Geneos Wealth Management Inc. lifted its position in shares of Charles River Laboratories International by 98.0% during the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after buying an additional 145 shares in the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Charles River Laboratories International Stock Up 2.5%

Shares of CRL opened at $186.08 on Wednesday. The stock has a market capitalization of $8.96 billion, a price-to-earnings ratio of -49.49, a price-to-earnings-growth ratio of 2.07 and a beta of 1.46. Charles River Laboratories International, Inc. has a 1 year low of $144.26 and a 1 year high of $228.88. The business’s 50 day simple moving average is $175.14 and its 200-day simple moving average is $182.81. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.36 and a quick ratio of 1.03.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, beating analysts’ consensus estimates of $1.96 by $0.10. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The firm had revenue of $995.83 million during the quarter, compared to the consensus estimate of $977.46 million. During the same period in the prior year, the company earned $2.34 EPS. The company’s quarterly revenue was up 1.2% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, equities analysts expect that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. JPMorgan Chase & Co. cut their price objective on Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating for the company in a research note on Monday, April 13th. Royal Bank Of Canada assumed coverage on shares of Charles River Laboratories International in a research note on Tuesday, April 14th. They set an “outperform” rating and a $215.00 target price on the stock. CLSA raised shares of Charles River Laboratories International from a “hold” rating to an “outperform” rating and lifted their price target for the company from $167.00 to $219.00 in a report on Friday, May 29th. Evercore reiterated an “outperform” rating and issued a $220.00 price target on shares of Charles River Laboratories International in a research report on Friday, May 8th. Finally, Mizuho set a $192.00 price objective on shares of Charles River Laboratories International in a research note on Friday, May 8th. Twelve equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $211.00.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.